292 related articles for article (PubMed ID: 35351276)
1. Targeted Therapy for Colorectal Cancer.
Sakata S; Larson DW
Surg Oncol Clin N Am; 2022 Apr; 31(2):255-264. PubMed ID: 35351276
[TBL] [Abstract][Full Text] [Related]
2. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
[TBL] [Abstract][Full Text] [Related]
3. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
4. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
5. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Treatment Landscape in
Tabernero J; Ros J; Élez E
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM
World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664
[TBL] [Abstract][Full Text] [Related]
8. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
[TBL] [Abstract][Full Text] [Related]
9. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
[TBL] [Abstract][Full Text] [Related]
10. Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.
Ten Hoorn S; Mol L; Sommeijer DW; Nijman L; van den Bosch T; de Back TR; Ylstra B; van Dijk E; van Noesel CJM; Reinten RJ; Nagtegaal ID; Koopman M; Punt CJA; Vermeulen L
Clin Colorectal Cancer; 2023 Mar; 22(1):67-75. PubMed ID: 36564280
[TBL] [Abstract][Full Text] [Related]
11. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.
Afrăsânie VA; Marinca MV; Alexa-Stratulat T; Gafton B; Păduraru M; Adavidoaiei AM; Miron L; Rusu C
Radiol Oncol; 2019 Sep; 53(3):265-274. PubMed ID: 31553708
[TBL] [Abstract][Full Text] [Related]
12. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract][Full Text] [Related]
13. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
14. The BEETS (JACCRO CC-18) trial: an observational and translational study of
Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y
Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF
García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S
Crit Rev Oncol Hematol; 2022 May; 173():103646. PubMed ID: 35344913
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Analysis of Treatment Pathways in Patients With BRAF
Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
[TBL] [Abstract][Full Text] [Related]
17. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
[TBL] [Abstract][Full Text] [Related]
18. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
